Prothrombin complex (Coagulation factors II, VII, IX, X) (PCC)

The prothrombin complex comprises four essential vitamin K-dependent coagulation factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X (StatPearls, NBK470444). These proteins are synthesized in the liver and undergo gamma-carboxylation, a process requiring vitamin K to enable their binding to phospholipid surfaces during clot formation (PubMed, PMID: 25031218). Within the coagulation cascade, these factors function as serine protease zymogens that are sequentially activated to generate thrombin, the central enzyme responsible for converting fibrinogen to fibrin (UniProt, P00742). This complex is a primary therapeutic target for treating acquired deficiencies, most notably for the rapid reversal of vitamin K antagonists like warfarin in patients experiencing life-threatening bleeding (FDA, Kcentra Label). Prothrombin complex concentrates (PCCs) provide a rapid and concentrated means of restoring hemostasis compared to fresh frozen plasma, significantly reducing the time to normalize the International Normalized Ratio (INR) (NEJM, 10.1056/NEJMoa1214307). Beyond anticoagulant reversal, these factors are critical in managing congenital deficiencies and liver disease-associated coagulopathy. Therapeutic intervention targeting this complex must be carefully monitored to balance the restoration of clotting with the risk of inducing a prothrombotic state.

Other names

Vitamin K-dependent coagulation factorsFactor II, VII, IX, and X complexProthrombin complex concentrateVitamin K-dependent clotting factors

Replacement therapy that provides a concentrated dose of vitamin K-dependent coagulation factors (II, VII, IX, X), allowing for the immediate restoration of thrombin generation and the coagulation cascade by bypassing the inhibition of vitamin K epoxide reductase caused by anticoagulants (StatPearls, NBK470444).